The even closer link between the thyroid and haemostasis

Massimo Franchini

doi:10.1160/TH12-11-0804

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2013; 109(02): 175-176
DOI: 10.1160/TH12-11-0804

Invited Editorial Focus

Schattauer GmbH

The even closer link between the thyroid and haemostasis

Massimo Franchini

¹Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy

› Author Affiliations

Abstract

Full Text

References

References
1 Franchini M, Montagnana M, Manzato F, Vescovi PP. Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost 2009; 35: 288-294.
2 Franchini M, Lippi G, Manzato F, Vescovi PP, Targher G. Hemostatic abnormalities in endocrine and metabolic disorders. Eur J Endocrinol 2010; 162: 439-451.
3 Vescovi PP, Favaloro EJ, Lippi G. et al. The spectrum of coagulation abnormalities in thyroid disorders. Semin Thromb Hemost 2011; 37: 7-10.
4 Squizzato A, Romualdi E, Büller HR, Gerdes VEA. Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007; 92: 2415-2420.
5 Marongiu F, Cauli C, Mariotti S. Thyroid, hemostasis and thrombosis. J Endocrinol Invest 2004; 27: 1065-1071.
6 Squizzato A, Romualdi E, Piantanida E. et al. Subclinical hypothyroidism and deep venous thrombosis: a pilot cross-sectional study. Thromb Haemost 2007; 97: 803-806.
7 Kootte RS, Stuijver DJF, Dekkers OM. et al. The incidence of venous thromboembolism in patients with overt hyperthyroidism: a retrospective multicentre cohort study. Thromb Haemost 2012; 107: 417-422.
8 Marongiu F, Barcellona D, Mameli A, Mariotti S. Thyroid disorders and hypocoagulability. Semin Thromb Hemost 2011; 37: 11-16.
9 Erem C. Thyroid disorders and hypercoagulability. Semin Thromb Hemost 2011; 37: 17-26.
10 Squizzato A, Gerdes VEA, Ageno W, Büller HR. The coagulation system in endocrine disorders: a narrative review. Intern Emerg Med 2007; 02: 76-83.
11 Krysiak R, Okopien B. Haemostatic effects of levothyroxine and selenomethionine in euthyroid patients with Hashimoto’s thyroiditis. Thromb Haemost 2012; 108: 973-980.
12 Verkleij CJN, Stuijver DJF, van Zaane B. et al. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinemia. Thromb Haemost 2013; 109: 214-220.
13 Stuijver DJF, van Zaane B, Romualdi E. et al. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Thromb Haemost 2012; 108: 1077-1088.
14 Franchini M, Lippi G, Targher G. Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review. Clin Appl Thromb Hemost 2011; 17: 387-392.
15 Kirchhof P, Lip GY, Van Gelder IC. et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106: 1012-1019.
16 Apostolakis S, Lip GY. Stroke prevention in non-valvular atrial fibrillation: can warfarin do better?. Thromb Haemost 2011; 106: 753-754.
17 Gallagher AM, Setakis E, Plumb JM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
18 Ogilvie IM, Welner SA, Cowell W. et al. Ischaemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients. Thromb Haemost 2011; 106: 34-44.
19 Lip GY, Piotrponikowski P, Andreotti F. et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. An Executive Summary of a joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost 2012; 108: 1009-1022.